Early Dual Antibiotic Therapy Cuts Blood Infection Rates
The SABEDTIO trial preliminary data show a significant reduction in prolonged Staphylococcus aureus bacteremia.
Updated on Oct. 26, 2026 in Life Sciences
Live Poll
Would you feel comfortable transitioning to oral medication sooner to shorten your hospital stay?
Preliminary results from the SABEDTIO trial reveal that early dual intravenous antibiotic therapy reduced rates of prolonged Staphylococcus aureus bacteremia to 6% compared to 16% in the control group. Researchers tested this approach to see if reversing standard escalation protocols could shorten bacteremia duration.
Why it matters
The study aims to determine if aggressive initial treatment protocols can improve patient outcomes and shorten the duration of bacteremia. Researchers are evaluating whether this method effectively optimizes antibiotic usage without compromising safety.
The study utilized experimental regimens including daptomycin plus ceftaroline or cefazolin plus ertapenem to treat 193 enrolled patients. Investigators also employed therapeutic drug monitoring to manage linezolid toxicity in older participants.
The players
West Virginia University
This public research university serves as the lead institution conducting the SABEDTIO trial.
IDWeek
This is an annual scientific meeting where experts in infectious diseases present the latest research and clinical data.
The details
Most patients in the trial successfully transitioned to oral antibiotics after 72 hours, though researchers noted instances of linezolid toxicity and relapsed bacteremia. The study, led by researchers at West Virginia University, continues to gather data as it moves toward its goal of 300 total participants.
Timeline
September 15, 2025: Trial enrollment officially began.
July 31, 2026: The trial enrollment period concluded.
October 21-24, 2026: Preliminary results were presented at IDWeek 2026.
The Big Picture
The SABEDTIO trial shifts the paradigm of Staphylococcus aureus treatment by challenging the traditional escalation approach to antibiotic therapy. By testing an early dual-therapy model, the study aims to refine clinical protocols for managing severe bacteremia.
These findings could lead to more effective clinical treatment protocols that reduce the time patients spend with prolonged bacteremia. Successful validation of this early therapy approach may influence future standard-of-care guidelines for hospital-based infectious disease management.
The takeaway
Reversing traditional antibiotic escalation may offer a more efficient path to clearing persistent bloodstream infections. Future results will clarify whether this dual-therapy method consistently reduces recovery times and hospital stays.
What happens next
Investigators are continuing to enroll patients to reach their target of 300 participants to complete the full dataset analysis.
Further reading
For more on evolving research, visit our Life Sciences section.
Source note: This article includes information reported by Contagionlive.
Live Poll
Would you feel comfortable transitioning to oral medication sooner to shorten your hospital stay?
